Search results for "Prognosis."

showing 10 items of 2044 documents

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

2017

Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms “uterine carcinosarcoma”, “uterine Malignant Mixed Müllerian Tumors”, “target therapies”,…

0301 basic medicineOncologyPathologyAngiogenesisCarcinosarcomas epigenetics genetics immunotherapy uterine cancer.medicine.medical_treatmentReviewEpigenesis Geneticlcsh:Chemistry0302 clinical medicineCarcinosarcomaAntibodies BispecificCarcinosarcomas Epigenetics Genetics Immunotherapy Uterine cancerMedicinegeneticsMolecular Targeted Therapylcsh:QH301-705.5Human Epidermal Growth Factor Receptor 2SpectroscopyNeovascularization PathologicGeneral MedicineEpithelial Cell Adhesion MoleculePrognosisComputer Science ApplicationsErbB ReceptorsSurvival Rate030220 oncology & carcinogenesisUterine NeoplasmsFemaleImmunotherapymedicine.medical_specialtyPoor prognosisMixed Tumor MullerianCatalysisuterine cancerInorganic Chemistry03 medical and health sciencesCancer stem cellInternal medicineBiomarkers TumorHumansTarget therapyPhysical and Theoretical ChemistrycarcinosarcomasMolecular BiologySurvival rateChemotherapyepigeneticsbusiness.industryOrganic ChemistryImmunotherapy030104 developmental biologylcsh:Biology (General)lcsh:QD1-999businessInternational Journal of Molecular Sciences
researchProduct

Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives.

2019

Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high morbidity and mortality; indeed the majority of OSCC has been lately identified in the advanced clinical stage (i.e., III or IV). Moreover, after primary treatment, recurrences and/or metastases are found in more than half of the patients (80% of cases within the first 2 years) and the 5-year survival rate is still lower than 50%, resulting in a serious issue for public health. Currently, histological investigation represents the “gold stan…

0301 basic medicineOncologySalivamedicine.medical_specialtyPhysiologyReviewlcsh:Physiology03 medical and health sciencesliquid biopsy salivary biomarkers circulating tumor DNA extracellular vesicles microRNAs early diagnosis prognosis oral squamous cell carcinoma0302 clinical medicinesalivary biomarkersInternal medicinePhysiology (medical)microRNAMedicineLiquid biopsyStage (cooking)Survival ratecirculating tumor DNAlcsh:QP1-981liquid biopsybusiness.industryCancerGold standard (test)medicine.diseasemicroRNAsoral squamous cell carcinomastomatognathic diseases030104 developmental biology030220 oncology & carcinogenesisBiomarker (medicine)prognosisbusinessextracellular vesiclesearly diagnosisFrontiers in physiology
researchProduct

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a…

2020

Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable and identifying the patient who will benefit from immunotherapy remains an issue. We performed a prospective study to investigate if soluble forms of the immune-checkpoints PD-1 (sPD-1), PD-L1 (sPD-L1), pan-BTN3As, BTN3A1, and BTN2A1, could be candidate to predict the response to immune-checkpoint blockade therapy. We evaluated the plasma levels in a learning cohort of metastatic clear cell renal carcinoma (mccRCC) patients treated with the anti-PD-1 agent nivolumab by ad hoc developed ELISA’s. Using specific cut-offs determined…

0301 basic medicineOncologySettore MED/06 - Oncologia MedicaProgrammed Cell Death 1 ReceptorB7-H1 Antigen0302 clinical medicineRenal cell carcinomaPD-1Immunology and AllergyProspective Studiespredictive biomarkerRC254-282ComputingMilieux_MISCELLANEOUSOriginal ResearchbiologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensfood and beveragesBTN3A1PrognosisTreatment efficacyKidney Neoplasms3. Good healthNivolumabOncology030220 oncology & carcinogenesisBiomarker (medicine)[SDV.IMM]Life Sciences [q-bio]/Immunologysoluble immune-checkpointsNivolumabResearch ArticlePD-L1medicine.medical_specialtyrenal cell carcinomabutyrophilinImmunology03 medical and health sciencesAntigens CDInternal medicinePD-L1mental disordersmedicineHumansIn patientCarcinoma Renal Cellbutyrophilinsbusiness.industryCancercirculating immune checkpointsPlasma levelsRC581-607medicine.diseasecirculating immune checkpoint030104 developmental biologyBTN2A1immunotherapy responsebiology.proteinImmunologic diseases. Allergybusiness
researchProduct

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.

2020

Background: Inflammation is a long-established hallmark of liver fibrosis and carcinogenesis. Eosinophils are emerging as crucial components of the inflammatory process influencing cancer development. The role of blood eosinophils in patients with hepatocellular carcinoma receiving systemic treatment is an unexplored field. Objective: The objective of this study was to analyse the prognostic role of the baseline eosinophil count in patients with sorafenib-treated hepatocellular carcinoma. Patients and Methods: A training cohort of 92 patients with advanced- or intermediate-stage sorafenib-treated hepatocellular carcinoma and two validation cohorts of 65 and 180 patients were analysed. Overa…

0301 basic medicineOncologySorafenibAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisCarcinoma HepatocellularInflammationAdult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Eosinophils; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Sorafenib; Survival Analysis; Young AdultCapecitabine03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineInternal medicineRegorafenib80 and overmedicineHumansPharmacology (medical)AgedAged 80 and overSettore MED/12 - Gastroenterologiabusiness.industryCarcinomaLiver NeoplasmsHepatocellularhepatocellular carcinomaEosinophilMiddle AgedSorafenibmedicine.diseasePrognosisSurvival AnalysisConfidence intervalEosinophils030104 developmental biologymedicine.anatomical_structureOncologychemistry030220 oncology & carcinogenesisHepatocellular carcinomaFemalemedicine.symptombusinessmedicine.drugTargeted oncology
researchProduct

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer

2019

Background: VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 are important proteins involved in the induction and development of a new blood vessel network through which the tumor is properly nourished and oxygenated. Objective: The aim of the study was to evaluate changes in VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 expression in endometrial cancer depending on its grade and to determine the VEGFR-1 to VEGFR-2 concentration ratio. Methods: The study group consisted of 45 patients diagnosed with endometrial cancer (G1, 17; G2, 15; G3, 13). The control group included 15 patients. VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 expression was assessed using the immunohistochemical method. Statistical analysis was carried out…

0301 basic medicineOncologyTumor angiogenesisVascular Endothelial Growth Factor Amedicine.medical_specialtyVascular Endothelial Growth Factor BVEGF-A/BAngiogenesisPharmaceutical ScienceArticle03 medical and health sciencesangiogenesis0302 clinical medicineInternal medicineMedicineHumansAdenomyosisRNA MessengerVascular Endothelial Growth Factor Receptor-1integumentary systemNeovascularization Pathologicbusiness.industryEndometrial cancerCancerVEGFR-1/2tumor angiogenesismedicine.diseasePrognosisImmunohistochemistryVascular Endothelial Growth Factor Receptor-2Endometrial Neoplasms030104 developmental biologymedicine.anatomical_structureadenomyosis030220 oncology & carcinogenesisCase-Control Studiesembryonic structuresendometrial cancercardiovascular systemImmunohistochemistryFemaleAnalysis of varianceNeoplasm GradingbusinessBiotechnologyBlood vesselCurrent Pharmaceutical Biotechnology
researchProduct

Current molecular and clinical insights into uveal melanoma (Review)

2021

Uveal melanoma (UM) represents the most prominent primary eye cancer in adults. With an incidence of approximately 5 cases per million individuals annually in the United States, UM could be considered a relatively rare cancer. The 90.95% of UM cases arise from the choroid. Diagnosis is based mainly on a clinical examination and ancillary tests, with ocular ultrasonography being of greatest value. Differential diagnosis can prove challenging in the case of indeterminate choroidal lesions and, sometimes, monitoring for documented growth may be the proper approach. Fine needle aspiration biopsy tends to be performed with a prognostic purpose, often in combination with radiotherapy. Gene expres…

0301 basic medicineOncologyUveal NeoplasmsCancer Researchmedicine.medical_specialtydiagnosisEnucleationBiology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeoplasm MetastasisGrading (tumors)MelanomaBiomarkers; Diagnosis; Epigenetics; Prognosis; Staging; Treatment; Uveal melanomamedicine.diagnostic_testtreatmentepigeneticsMelanomaGene Expression ProfilingCancerbiomarkersArticlesstagingmedicine.diseasePrognosisPrimary tumor030104 developmental biologyFine-needle aspirationOncology030220 oncology & carcinogenesisMutationDifferential diagnosisuveal melanomaGNAQ
researchProduct

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

2016

Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metastases (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metast…

0301 basic medicineOncologyendocrine system diseasesColorectal cancerLiver metastasimedicine.medical_treatmentColorectal Neoplasmmedicine.disease_cause0302 clinical medicineLiver metastasisHematologyTumorLiver NeoplasmsHematologyPrognosisSurvival RateOncologyLiver Neoplasm030220 oncology & carcinogenesisMeta-analysisKRASColorectal NeoplasmsHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognostic biomarkerPrognosiResectionBRAFProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicineBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologymedicineKRASBiomarkers TumorHepatectomyHumansneoplasmsSurvival ratebusiness.industrymedicine.diseaseColorectal cancerdigestive system diseasesClinical trial030104 developmental biologyMutationBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers; Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologyHepatectomyGeriatrics and GerontologybusinessBiomarkersCritical reviews in oncology/hematology
researchProduct

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

2017

Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the a…

0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyPancreatic ductal adenocarcinomaendocrine system diseasesmedicine.medical_treatment[SDV]Life Sciences [q-bio]Immunologybtn3apancreatic ductal adenocarcinomalcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicineImmunology and AllergyComputingMilieux_MISCELLANEOUSbusiness.industrycd277Aggressive cancerCancerPrognosis MarkerImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensbutyrophilin 3 adigestive system diseases3. Good health[SDV] Life Sciences [q-bio]030104 developmental biologyOncology030220 oncology & carcinogenesisimmunotherapybusinesslcsh:RC581-607Research Article
researchProduct

Prognostic impact and implications of extra-capsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis.

2015

The extranodal extension (ENE) of nodal metastasis (i.e. the extension of tumor cells through the nodal capsule into the perinodal adipose tissue) has recently emerged as an important prognostic factor in different types of malignancies. However, the tumor-node-metastasis (TNM) staging system for colorectal cancer does not consider it as a prognostic parameter. Therefore, we conducted a systematic review and meta-analysis to determine the prognostic role of ENE in patients with lymph node-positive colorectal cancer.Two independent authors searched PubMed and SCOPUS until 7 January 2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects wit…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerExtra-capsular extensionColon cancer; ENE; Extra-capsular extension; Extra-nodal extension; Lymph node metastasis; Rectal cancer03 medical and health sciences0302 clinical medicinecolon cancer; extracapsular extension; extranodal extension; lymph node metastasis; rectal cancerInternal medicineHumansMedicineextracapsular extensionRectal cancerProspective cohort studyLymph nodeProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelHazard ratioCancerextranodal extensionHematologyPrognosismedicine.diseaseColon cancerTreatment Outcome030104 developmental biologymedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisMeta-analysisENEextranodal extension extracapsular extension lymph node metastasis colon cancer rectal cancerRegression AnalysisT-stageExtra-nodal extensionLymph NodesNeoplasm Recurrence LocalColorectal Neoplasmsbusiness
researchProduct

Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma

2019

Gastroesophageal adenocarcinoma (GEA) represents a very heterogeneous disease and patients in advanced stages have a very poor prognosis. Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge. Despite improvement in clinical outcomes obtained by adding trastuzumab to first-line platinum-based chemotherapy, no other anti-HER2 agents used first-line or beyond progression have demonstrated any benefit. Several factors contribute to this failure. Among them, variable HER2 amplification assessment, tumour heterogeneity, molecular mechanisms of resistance and microenvironmental factors could limit the effecti…

0301 basic medicineOncologymedicine.medical_specialtyEsophageal NeoplasmsTumour heterogeneityReceptor ErbB-2DiseaseDrug resistanceAdenocarcinomaGastroesophageal Junction AdenocarcinomaGenetic Heterogeneity03 medical and health sciences0302 clinical medicineStomach NeoplasmsTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansPrecision Medicineskin and connective tissue diseasesGastroesophageal adenocarcinomabusiness.industryGene AmplificationHematologyPrognosisPrecision medicineProgression-Free SurvivalBlockade030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisEsophagogastric Junctionbusinessmedicine.drugAnnals of Oncology
researchProduct